AstraZeneca's selumetinib enters late-stage lung cancer study

10/24/2013 | PharmaTimes (U.K.)

AstraZeneca has initiated a Phase III trial to assess the efficacy of its experimental MEK inhibitor selumetinib, in combination with docetaxel, as a second-line treatment for locally advanced or metastatic KRAS mutation-positive nonsmall-cell lung cancer. The firm said the study, which will involve 220 centers and 634 patients, will be the biggest prospective trial involving this patient population.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY